Anemia of cancer is characterized by ineffective erythropoiesis, which is due to a number of factors. One of the most important among these is abnormal iron metabolism. Iron deficiency can occur ...

In none of 5 patients with refractory anemia and hypercellular bone marrow was erythropoiesis detectably affected. In 1 patient with the anemia of cirrhosis of the liver no response was obtained ...

Erythropoiesis was evaluated in 16 patients ... a degree of hemolysis that could easily be met by the normal bone marrow. The anemia could be ascribed primarily to defective erythropoietin ...

A review of targeted therapies for anemia in patients with lower-risk myelodysplastic syndromes and myelofibrosis that improve transfusion independence and hemoglobin levels.

Erythropoiesis-stimulating agent (ESA) treatment before or early after regular transfusion therapy improved overall survival ...

Converting from the long-acting ESA methoxy polyethylene glycol-epoetin-ß (MPG-EPO) to thrice weekly vadadustat is feasible for the hemodialysis population.

If anemia is severe, doctors may use drugs called erythropoiesis-stimulating agents to increase red blood cell production in the bone marrow. These drugs work similarly to the hormone ...

Take-home messages from the guidelines include: Patients with non-transfusion-dependent beta-thalassemia should be considered ...

Leukemia often results in severe anemia, which may significantly contribute to patient mortality and morbidity. However, the mechanisms underlying defective erythropoiesis in leukemia have not ...

Table 2. Recommendations for the use of erythropoiesis-stimulating agents in patients with nonhematological malignancies. Organization Anemia related to chemotherapy Untreated patients Patients ...